How Tarsus Pharmaceuticals’ latest earnings and guidance updates shape the stock debate

Tarsus Pharmaceuticals (TARS) reported second quarter 2026 revenue of $173.91 million and a net loss of $18.55 million, alongside higher full year XDEMVY sales guidance that gives investors fresh numbers to assess.

For the first half of 2026, Tarsus Pharmaceuticals reported revenue of $335.97 million. The company also reported a net loss of $25.52 million for the same period, which included basic loss per share from continuing operations of $0.59.

Against this backdrop, Tarsus Pharmaceuticals’ share price has moved higher in recent weeks, with a 7 day share price return of 5.66% and a 30 day share price return of 11.44%, even though the year to date share price return is down 19.78%. Over a longer horizon, total shareholder return of 29.40% over one year and very large gains over three years indicate that recent volatility sits within a strong multi year run.

If you are looking beyond Tarsus Pharmaceuticals for other potential healthcare opportunities, it could be worth scanning AI driven treatments and tools through 43 healthcare AI stocks

Tarsus Pharmaceuticals now looks like a business with real commercial momentum, yet the stock has already bounced in recent weeks. So are you paying up for that progress, or is the current price still reasonable?

Most Popular Narrative: 31.2% Undervalued

The most followed narrative currently sees Tarsus Pharmaceuticals worth $94.11 per share compared with a last close of $64.79, which frames a sizeable valuation gap for investors to interrogate.

Accelerated patient and physician adoption of XDEMVY, driven by a robust direct-to-consumer campaign and increased unaided awareness, points to ongoing demand expansion among an estimated 25 million potential U.S. patients, suggesting material runway for future top-line revenue growth.

Want to see what has to happen for that valuation to make sense? The narrative leans on steep revenue expansion, a sharp profit swing, and a compressed future earnings multiple. The mix of these moving parts is what really matters.

Result: Fair Value of $94.11 (UNDERVALUED)

However, the Tarsus Pharmaceuticals story depends heavily on XDEMVY continuing to perform, and on high commercial spending eventually translating into clear and sustained profitability.

Next Steps

With sentiment around Tarsus Pharmaceuticals leaning positive but dependent on execution, it makes sense to check the data yourself and decide quickly where you stand. To see what investors are currently optimistic about, review the 4 key rewards.

Looking for more investment ideas beyond Tarsus Pharmaceuticals?

If Tarsus Pharmaceuticals has sharpened your focus, do not stop here. Use the Simply Wall St Screener to uncover fresh ideas that fit your investing style.

• Spot potential value opportunities early by scanning screener containing 21 high quality undiscovered gems that combine solid fundamentals with lower market attention.
• Strengthen your core holdings by reviewing companies in the solid balance sheet and fundamentals stocks screener (48 results) that prioritize financial resilience.
• Dial down portfolio stress by checking out 83 resilient stocks with low risk scores that score well on stability and risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.